Quick Listen: Scrip's Five Must-Know Things
In this week's podcast edition of Five Must-Know Things: time runs out to scale the next patent cliff; Novartis searches for new blockbuster; Boehringer Ingelheim’s R&D spending pays off; Shanghai eyes mRNA vaccines as COVID cases rise; and the global pharma R&D pipeline hits new heights.
Join us for an audio catch-up on the major events in the biopharma industry over the past business week, as reported by Scrip's global team, in this podcast version of Five Must-Know Things.
This episode covers insights for the business week ended 8 April 2022, including: time runs out to scale the next patent cliff; Novartis AG searches for a new blockbuster; Boehringer Ingelheim GmbH’s R&D spending pays off; Shanghai eyes mRNA vaccines as COVID cases rise; and the global pharma R&D pipeline hits new heights.
This and all our other podcasts are available on the Informa Pharma Intelligence channel on Apple Podcasts, Google Podcasts, SoundCloud, TuneIn and Spotify Podcasts, and via smart speakers if one of these platforms has been set up as your default podcast provider.
Stories mentioned in this episode:
(Also see "The Next Big Patent Cliff Is Coming, And Time Is Running Out To Pad The Fall" - Scrip, 4 Apr, 2022.)
(Also see "Can Novartis Break Back Into The US Top Five? It Is Going To Need Bigger Blockbusters" - Scrip, 6 Apr, 2022.)
(Also see "Late-Stage Pipeline Blooming At Boehringer As R&D Spend Soars" - Scrip, 5 Apr, 2022.)
(Also see "Facing COVID Surge, China Revises Course To Support Imported mRNA Vaccines" - Scrip, 31 Mar, 2022.)
(Also see "COVID-19 Factor Wanes But Pharma’s R&D Pipeline Hits Record Heights" - Scrip, 31 Mar, 2022.)